UNLOXCYT™ (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell ...

Full Year 2024 Results Key Financial Results Net loss: US$56.2m (loss ...

Reports FY24 revenue $41k vs $103k last yearLight Up your Portfolio with Spark:Easily identify stocks' risks and opportunities. Discover ...

Sun Pharma will acquire Checkpoint Therapeutics for $355 million, expected to close by Q2 2025. The deal strengthens Sun Pharma’s oncology portfolio with FDA-approved UNLOXCYT for advanced cutaneous ...

Sun Pharmaceutical Industries has agreed to acquire Checkpoint Therapeutics, a company specialising in immunotherapy and targeted oncology treatments, for an aggregate upfront price of $355m. The ...

Please see full Prescribing Information. Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and ...

(MENAFN- GlobeNewsWire - Nasdaq) UNLOXCYTTM (cosibelimab-ipdl) approved by U.S. FDA as first and only anti-PD-L1 treatment for advanced cutaneous squamous cell carcinoma WALTHAM, Mass., March 28 ...

WALTHAM, Mass., March 28, 2025 (GLOBE NEWSWIRE) -- Checkpoint Therapeutics, Inc. (“Checkpoint”) (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted ...

Please see full Prescribing Information. Checkpoint Therapeutics, Inc. is a commercial-stage immunotherapy and targeted oncology company focused on the acquisition, development and commercialization ...

Checkpoint Therapeutics, Inc. ("Checkpoint") (Nasdaq: CKPT), a commercial-stage immunotherapy and targeted oncology company, today announced financial ...